^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EU211

    i
    Other names: hTERT T cell therapy, TNT, TERT-induced adoptive T cell therapy, telomerase reverse transcriptase-induced natural T cell therapy, TERT 4-1BB CTL, TERT-induced natural T cell therapy, TERTiNT, EU211
    Associations

    News

    Trials
    Company:
    Eutilex
    Drug class:
    CD137 agonist, hTERT inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Phase 1 trial of 4-1BB-based adoptive T-cell therapy targeting human telomerase reverse transcriptase in patients with advanced refractory solid tumors. (PubMed, Cytotherapy)
    The generation of TERTiNTs was feasible and safe and provided an interesting disease control rate in heavily pre-treated cancer patients.
    P1 data • Clinical Trial,Phase I • Journal • Metastases
    |
    CD8 (cluster of differentiation 8) • TERT (Telomerase Reverse Transcriptase)
    |
    cyclophosphamide • fludarabine IV • EU204 • EU211